{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Empagliflozin+25+mg",
    "query": {
      "intervention": "Empagliflozin 25 mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 44,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Empagliflozin+25+mg&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T06:48:25.443Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04907214",
      "title": "SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Obesity",
        "Pre-diabetes"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 25 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 29,
      "start_date": "2021-07-29",
      "completion_date": "2023-12-08",
      "has_results": true,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-09-30T06:48:25.443Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04907214"
    },
    {
      "nct_id": "NCT05426525",
      "title": "Use of Empagliflozin to Treat Prediabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "PreDiabetes",
        "Prediabetic State",
        "Overweight and Obesity"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Multivitamin-Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 60,
      "start_date": "2022-10-13",
      "completion_date": "2026-08-20",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-09-30T06:48:25.443Z",
      "location_count": 1,
      "location_summary": "Corvallis, Oregon",
      "locations": [
        {
          "city": "Corvallis",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05426525"
    },
    {
      "nct_id": "NCT07053319",
      "title": "SGLT2i, Pioglitazone, and Ketone Production in T2D",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 25 MG",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 64,
      "start_date": "2026-05-11",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-09-30T06:48:25.443Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07053319"
    },
    {
      "nct_id": "NCT06609356",
      "title": "Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus",
        "Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY)",
        "MODY2 Diabetes",
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Study Visit 1",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Study Visit 2",
          "type": "PROCEDURE"
        },
        {
          "name": "Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 27,
      "start_date": "2025-07-03",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-09-30T06:48:25.443Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06609356"
    },
    {
      "nct_id": "NCT05512130",
      "title": "Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 18,
      "start_date": "2022-08-17",
      "completion_date": "2023-06-30",
      "has_results": false,
      "last_update_posted_date": "2022-08-23",
      "last_synced_at": "2026-09-30T06:48:25.443Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05512130"
    },
    {
      "nct_id": "NCT03193684",
      "title": "Empagliflozin and Hepatic Glucose Metabolism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatic Glucose Metabolism"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 25 MG",
          "type": "DRUG"
        },
        {
          "name": "Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 72,
      "start_date": "2018-05-20",
      "completion_date": "2024-01-30",
      "has_results": true,
      "last_update_posted_date": "2024-08-28",
      "last_synced_at": "2026-09-30T06:48:25.443Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03193684"
    },
    {
      "nct_id": "NCT05510115",
      "title": "Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Polycystic Kidney, Autosomal Dominant"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 50,
      "start_date": "2022-11-18",
      "completion_date": "2026-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-09-30T06:48:25.443Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05510115"
    },
    {
      "nct_id": "NCT06229678",
      "title": "Ketones, SGLT2, HFrEF",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Type2diabetes",
        "Heart Failure With Reduced Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 25 MG Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Acipimox 250 Mg Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 71,
      "start_date": "2024-01-25",
      "completion_date": "2027-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-09-30T06:48:25.443Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06229678"
    },
    {
      "nct_id": "NCT01131676",
      "title": "BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "BI 10773 low dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo BI 10773 high dose",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 high dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo BI 10773 low dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7064,
      "start_date": "2010-07",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-05-16",
      "last_synced_at": "2026-09-30T06:48:25.443Z",
      "location_count": 170,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 140 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01131676"
    },
    {
      "nct_id": "NCT03852901",
      "title": "Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Empaglifozin",
        "Physiological Effects of Drugs",
        "Hypoglycemic Agents",
        "Sodium-Glucose Transporter 2 Inhibitors"
      ],
      "interventions": [
        {
          "name": "empagliflozin (Jardiance) 25 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Aging (NIA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2019-03-28",
      "completion_date": "2021-12-13",
      "has_results": true,
      "last_update_posted_date": "2022-08-02",
      "last_synced_at": "2026-09-30T06:48:25.443Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03852901"
    }
  ]
}